Improving treatment for brain cancer using a CMV peptide vaccine
Expanding CMV peptide vaccine with novel combinations and pathologies
['FUNDING_R03'] · WASHINGTON UNIVERSITY · NIH-10950990
This study is testing a new vaccine designed to help children's immune systems fight aggressive brain tumors linked to a virus called cytomegalovirus (CMV), with the hope of improving their chances of survival and overall well-being.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10950990 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel peptide vaccine targeting the human cytomegalovirus (CMV) antigen found in certain aggressive brain tumors, particularly in pediatric patients. The approach aims to harness the immune system to recognize and attack cancer cells more effectively than traditional treatments like chemotherapy and radiation. By investigating the presence of CMV antigens in various brain tumor types, the study seeks to enhance the understanding of how to improve survival rates and quality of life for affected children. The research includes preliminary trials that have shown promising immune responses in patients treated with the vaccine.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with high-grade gliomas, diffuse midline gliomas, recurrent medulloblastomas, or recurrent ependymomas.
Not a fit: Patients with brain tumors that do not express CMV antigens or those who are not pediatric patients may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for children with aggressive brain tumors, potentially improving survival rates and quality of life.
How similar studies have performed: Preliminary results from similar immunotherapy approaches have shown promise, indicating that targeting CMV antigens may be a viable strategy for treating certain brain tumors.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: THOMPSON, ERIC — WASHINGTON UNIVERSITY
- Study coordinator: THOMPSON, ERIC
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.